MeiraGTx Holdings PLC (MGTX)vsMerck & Company Inc (MRK)
MGTX
MeiraGTx Holdings PLC
$9.71
-0.46%
HEALTHCARE · Cap: $884.56M
MRK
Merck & Company Inc
$146.35
+3.83%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 16647% more annual revenue ($66.57B vs $397.50M). MGTX leads profitability with a 19.9% profit margin vs 4.8%. MGTX trades at a lower P/E of 10.7x. MGTX earns a higher WallStSmart Score of 61/100 (C+).
MGTX
Buy61
out of 100
Grade: C+
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MGTX.
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Strong operational efficiency at 76.0%
Revenue surging 8609.0% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : MGTX
The strongest argument for MGTX centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 19.9% and operating margin at 76.0%. Revenue growth of 8609.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : MGTX
The primary concerns for MGTX are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
MGTX profiles as a growth stock while MRK is a value play — different risk/reward profiles.
MGTX carries more volatility with a beta of 1.35 — expect wider price swings.
MGTX is growing revenue faster at 8609.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MGTX scores higher overall (61/100 vs 36/100), backed by strong 19.9% margins and 8609.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MeiraGTx Holdings PLC
HEALTHCARE · BIOTECHNOLOGY · USA
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?